Prospective Cohort of Opiate Dependent Patients on Buprenorphine/Naloxone for Maintenance (Project BEST)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00622596|
Recruitment Status : Completed
First Posted : February 25, 2008
Last Update Posted : August 24, 2016
|Condition or disease||Intervention/treatment||Phase|
|Opiate Dependence||Other: Mobile Access||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||200 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Prospective Cohort of Opiate Dependent Patients on Buprenorphine/Naloxone for Maintenance|
|Study Start Date :||October 2003|
|Actual Primary Completion Date :||September 2008|
|Actual Study Completion Date :||September 2008|
Experimental: Mobile Access to Buprenorphine
High risk populations accessing a mobile health care system can obtain Buprenorphine for treatment.
Other: Mobile Access
Subjects would access buprenorphine through mobile access. On day 1: 8 mg of buprenorphine, then on Day 2: 16 mg daily of buprenorphine sublingually.
- Attendance [ Time Frame: 10/1/03-9/30/08 ]To assess the feasibility and efficacy of the use of buprenorphine to treat opioid dependence in high risk populations accessing a mobile health care system using tracked attendance.
- Opioid free urine toxicology [ Time Frame: 10/1/03-9/30/08 ]To assess the feasibility and efficacy of the use of buprenorphine to treat opioid dependence in high risk populations accessing a mobile health care system using incidence of opioid free urine toxicology.
- Access to other health care, incarceration, hospitalization acceptability of the site of care from both patient and provider perspectives, and attendance and adherence to counseling. [ Time Frame: 10/1/03-9/30/08 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00622596
|United States, Connecticut|
|Yale University School of Medicine|
|New Haven, Connecticut, United States, 06510|
|Principal Investigator:||Frederick L Altice, MD||Yale University School of Medicine/AIDS Program|